KCM
BOLD

Kingdon Capital Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Kingdon Capital Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-108,031
Closed -$4.21M – 89
2019
Q1 		$4.21M Hold
108,031
– – 0.56% 47
2018
Q4 		$2.3M Buy
+108,031
New +$2.79M 0.35% 48

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kingdon Capital Management's BOLD Position: Q2 2019 in Review

Kingdon Capital Management sold out of Audentes Therapeutics, Inc (BOLD) in Q2 2019, closing a stake of 108,031 shares — an estimated $4.21M sold.

Kingdon Capital Management first reported a position in BOLD in Q4 2018 and held it in 2 quarters. The position peaked at $4.21M in Q1 2019. 147 funds tracked by Wall St. Rank hold BOLD as of Q2 2019.

  • Kingdon Capital Management reported no remaining Audentes Therapeutics, Inc position as of Q2 2019 after selling out during the quarter.
  • Kingdon Capital Management sold 108,031 Audentes Therapeutics, Inc shares in Q2 2019, an estimated $4.21M.
  • Kingdon Capital Management first reported a position in Audentes Therapeutics, Inc in Q4 2018 and held it in 2 quarters.
  • Kingdon Capital Management's Audentes Therapeutics, Inc position peaked at $4.21M in Q1 2019.
  • 147 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q2 2019.

Based on Kingdon Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.